Introduction {#s1}
============

Prismatic clinical scenario {#s1a}
---------------------------

A 9-year-old boy presented to a local emergency department (ED) with chronic abdominal pain, acute onset of nausea and vomiting for the previous 24 hours. Physical examination revealed an ill-appearing, thin male with tachycardia (pulse 110 bpm), mild hypotension (85/60 mm Hg), signs of dehydration, and hyperpigmentation. Laboratory testing showed hyponatremia (sodium 129 mEq/L), hyperkalemia (potassium 5.8 mEq/L) and hypoglycemia (glucose 55 mg/dL). Despite urgent fluid resuscitation with 2 intravenous boluses of normal saline and a bolus of 10% dextrose, hypotension persisted. Due to clinical and biochemical features suggestive of primary adrenal insufficiency (AI), blood was drawn for measurement of adrenocorticotropic hormone (ACTH) and cortisol levels prior to administering 75 mg of intravenous hydrocortisone sodium succinate (Solu-Cortef). He was admitted and diagnosis confirmed. Treatment was initiated with hydrocortisone and fludrocortisone. The patient and family received education for the management of primary AI and prevention of adrenal crises.

Two years later he developed acute gastroenteritis with fever, vomiting and diarrhea while visiting his grandparents in a rural area. He received triple his usual dose of oral hydrocortisone, but vomited within 10 minutes. Grandparents had hydrocortisone sodium succinate available for intramuscular injection, but did not know how to administer it and called 911. The patient was unresponsive on arrival of the ambulance 20 minutes later. Grandparents informed the emergency medical technicians (EMT) that he needs to receive hydrocortisone sodium succinate intramuscularly for AI. Due to emergency medical services (EMS) policy, the EMTs were not allowed to administer the child's personal supply of hydrocortisone sodium succinate and did not have an alternative medication on the ambulance. Glucometer revealed a blood glucose of 30 mg/dL. While EMTs attempted to place an intravenous catheter, he experienced a seizure. He was intubated and received intravenous dextrose with cessation of the seizure. He was transported to a local ED that was 30 minutes away. In the ED, he was given 75 mg intravenous hydrocortisone sodium succinate and was admitted to the intensive care unit where he later died of complications related to prolonged hypoglycemia and aspiration pneumonitis.

Background {#s2}
==========

Adrenal crisis is a life-threatening condition that can be prevented by recognition in which patients with AI must receive additional glucocorticoids when under physiological stress. Adrenal crisis can also occur as the initial clinical presentation of AI. Appropriate management requires immediate recognition of the clinical signs, symptoms and biochemical profile of AI and the triggers for adrenal crisis. Therefore, primary care, urgent care and ED providers must be trained to recognize the diverse clinical circumstances in which AI can occur. In children with known AI, parents and care providers must be familiar with the administration of maintenance and stress dose glucocorticoid therapy to prevent adrenal crises. This can be facilitated by providing the family with a written Adrenal Insufficiency Action Plan and Emergency Care Letter. Currently, hydrocortisone, or an equivalent synthetic glucocorticoid, is not available on most ambulances for emergency administration by EMS personnel. In addition, EMT training on the use of patient's home medication is not widely employed. Both of these situations can lead to life-threatening delays in providing appropriate therapy to prevent or treat adrenal crises.

AI is a significant cause of morbidity and mortality in children[@R1] with an annual estimated incidence of adrenal crisis of 5--10 episodes per 100 patient-years, with increasing rates in some countries.[@R4] One in every 200 episodes of adrenal crisis results in death.[@R5] Therefore, the goal of this working group was to raise awareness on the importance of early recognition and provide guidance on the emergency management of AI in children during illnesses, particularly in the outpatient, EMS and ED settings.

Etiology {#s3}
========

AI is characterized by impaired adrenal synthesis of glucocorticoids. When reduced production of mineralocorticoid (aldosterone) is present it is associated with hyponatremia due to salt-wasting and reciprocal hyperkalemia. AI can be categorized as primary, where the defect is in the adrenal gland, or secondary (central), where the defect is due to hypothalamic and/or pituitary dysfunction. In the central forms deficient secretion of ACTH leads to atrophy of the zona fasciculata in the adrenal cortex (the source of glucocorticoids); mineralocorticoid production by the zona glomerulosa is preserved because the renin-angiotensin system is intact.

The most common cause of primary AI in children is congenital adrenal hyperplasia (CAH), the leading cause of atypical genitalia in female newborns. Less common causes of primary AI include autoimmune adrenalitis (isolated or part of autoimmune polyglandular syndromes), infections, bilateral adrenal hemorrhage, and various genetic syndromes including X linked adrenoleukodystrophy[@R6] (see [table 1](#T1){ref-type="table"} and [box 1](#B1){ref-type="boxed-text"}).

###### 

Congenital causes of adrenal insufficiency

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                                                                              Affected gene                                                                                Clinical phenotype
  -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  **Primary**                                                                                                                                                                         

  CAH                                                                                                                                                                                 

   21-α-hydroxylase deficiency                                                           *CYP21A2*                                                                                    46, XX DSD/androgen excess; salt-wasting

   3-β**-**hydroxysteroid dehydrogenase deficiency                                       *HSD3B2*                                                                                     Ambiguous genitalia/salt-wasting

   11-β**-**hydroxylase deficiency                                                       *CYP11B2*                                                                                    46, XX DSD/androgen excess; hypertension (not infants)

   P450 side-chain cleavage syndrome                                                     *CYP11A*                                                                                     46, XY DSD; salt-wasting, hypogonadism

   Lipoid hyperplasia                                                                    *StAR*                                                                                       46, XY DSD; salt-wasting; hypogonadism

   P450 oxidoreductase deficiency (PORD)                                                 *POR*                                                                                        46, XY DSD, salt-wasting, hypogonadism, Antley-Bixler malformation; altered drug metabolism

  Congenital adrenal hypoplasia                                                          *SF-1*\                                                                                      46, XY DSD, gonadal insufficiency
                                                                                         *(NR5A1)*                                                                                    

  *DAX-1 (NROB1)*                                                                        Hypogonadotropic hypogonadism                                                                

  *CDKN1C*                                                                               IMAGe syndrome (intrauterine growth retardation, metaphyseal dysplasia, genital anomalies)   

  Triple A or Allgrove                                                                   *AAAS*                                                                                       Achalasia, alacrima

  Isolated familial glucocorticoid deficiency (FGD)                                      *MC2R,*\                                                                                     Tall stature, normal mineralocorticoid production
                                                                                         *MRAP*                                                                                       

  FGD--DNA repair defect                                                                 *MCM4*                                                                                       NK-cell defect, short stature, recurrent viral infections, microcephaly, chromosomal breakage

  Glucocorticoid resistance                                                              *GCCR*                                                                                       Mineralocorticoid/androgen excess

  Metabolic diseases                                                                                                                                                                  

   Adrenoleukodystrophy                                                                  *ABCD1*                                                                                      Neurologic deterioration

   Zellweger                                                                             *PEX*                                                                                        Cerebrohepatorenal syndrome

   Smith-Lemli-Opitz                                                                     *DHCR7*                                                                                      46, XY sex reversal, polydactyly, mental retardation

   Wolman                                                                                *LIPA*                                                                                       Hepatomegaly

  Mitochondrial disease                                                                                                                                                               

   Kearns-Sayre                                                                                                                                                                       Ophthalmoplegia, myopathy

  **Secondary: hypothalamus**                                                                                                                                                         

  Holoprosencephaly                                                                      *GLI2,*\                                                                                     
                                                                                         *FGF8*                                                                                       

  CRH deficiency                                                                                                                                                                      

  Maternal hypercortisolemia                                                                                                                                                          

  **Secondary: pituitary/hypothalamus**                                                                                                                                               

  Isolated ACTH deficiency                                                               *TPIT*                                                                                       

  Multiple anterior pituitary hormone deficiencies due to pituitary aplasia/hypoplasia   *HESX1*                                                                                      Septo-optic dysplasia (optic nerve hypoplasia), nystagmus

  *PROP1*                                                                                                                                                                             

  *LHX4*                                                                                                                                                                              

  *OTX2*                                                                                 Anophthalmia, developmental delay                                                            

  *SOX3*                                                                                 X linked, mental retardation, ectopic posterior pituitary                                    

  Isolated ACTH deficiency                                                               *TPIT (TBX19)*                                                                               

  Proopiomelanocortin deficiency                                                         *POMC*                                                                                       Severe early-onset hyperphagic obesity, red hair

  Proprotein convertase 1 mutation                                                       *PCSK1*                                                                                      Hypoglycemia, malabsorption, gonadotropin deficiency
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACTH, adrenocorticotropic hormone; CAH, congenital adrenal hyperplasia; CRH, corticotropin-releasing hormone; DSD, disorder of sex development; NK, natural killer.

###### Acquired causes of adrenal insufficiency

**Primary**

-   Autoimmune adrenalitis (Addison disease)

    -   Isolated.

    -   Autoimmune polyendocrinopathy type 1.

    -   Autoimmune polyendocrinopathy type 2.

-   Bilateral hemorrhage/infarction

    -   Trauma.

    -   Waterhouse-Friderichsen syndrome.

    -   Anticoagulation.

-   Drug effect: mifepristone, aminoglutethimide, mitotane, ketoconazole, etomidate, metyrapone, rifampin, phenytoin, barbiturates, tyrosine kinase inhibitors (eg, sunitinib)

-   Infection

    -   Viral: HIV, cytomegalovirus.

    -   Fungal: coccidioidomycosis, histoplasmosis, blastomycosis, cryptococcosis.

    -   Mycobacterial: tuberculosis.

    -   Amebic.

-   Infiltrative

    -   Hemochromatosis, histiocytosis, sarcoidosis, amyloidosis, neoplasm.

-   Surgery: bilateral adrenalectomy

**Secondary: hypothalamus**

-   Corticosteroid withdrawal after prolonged administration (inhaled, intranasal, oral, rectal, intravenous and topical).

-   Corticosteroid withdrawal after parenteral administration of high doses of potent and longer acting preparations (intramuscular, intradermal and intra-articular routes).

-   Drug effect: megestrol, mitotane, medroxyprogesterone, rifampin, phenytoin, barbiturates, tyrosine kinase inhibitors (eg, sunitinib).

-   Inflammatory disorders.

-   Trauma.

-   Radiation therapy.

-   Surgery.

-   Tumors: craniopharyngioma, germinoma.

-   Infiltrative disease: sarcoidosis, histiocytosis.

**Secondary: pituitary**

-   Corticosteroid withdrawal after prolonged administration.

-   Trauma.

-   Tumor: craniopharyngioma.

-   Radiation therapy.

-   Lymphocytic hypophysitis.

The most common cause of secondary (central) AI is low ACTH due to iatrogenic suppression of the pituitary corticotrophs by prolonged use of supraphysiological doses of oral glucocorticoids typically prescribed for the treatment of medical conditions including but not limited to asthma, hematologic/oncologic conditions, inflammatory bowel disorders, rheumatologic conditions, nephrotic syndrome, neurologic disorders, postneurosurgical procedures, and hematopoietic and solid organ transplants. Glucocorticoids administered by intra-articular, topical, intradermal, and inhaled routes may also suppress the hypothalamic-pituitary-adrenal (HPA) axis.[@R9] Other medications, such as megestrol acetate, ketoconazole, and mifepristone, also impair adrenal function via direct and indirect mechanisms. Less common secondary causes of ACTH deficiency involving the pituitary and hypothalamus include tumors, radiation exposure, congenital anomalies, and specific gene defects ([table 1](#T1){ref-type="table"} and [box 1](#B1){ref-type="boxed-text"}). Inherited forms of ACTH deficiency are usually associated with additional pituitary hormone deficiencies.

The magnitude of suppression of the HPA axis in relation to dose, duration, and type of glucocorticoid therapy can vary among individuals due to variability in glucocorticoid pharmacokinetics and interindividual glucocorticoid receptor sensitivity.[@R11] Generally, the HPA axis recovers rapidly when the duration of glucocorticoid treatment is short, that is, less than 7--10 days, even when high doses are used. In these circumstances, it is appropriate to discontinue glucocorticoids abruptly. However, if the duration of therapy is 3 weeks or longer, it is recommended that the glucocorticoid dose be tapered gradually to avoid precipitating symptoms of steroid dependence and/or AI.[@R12] Protracted use of supraphysiological glucocorticoid doses may result in severe adrenal gland atrophy and prolonged AI lasting up to 34 weeks requiring glucocorticoid tapering to be extended over many months.[@R13]

A Cochrane review of 8 studies of 9218 children with acute lymphoblastic leukemia treated with prolonged courses of supraphysiological doses of long-acting glucocorticoids, including dexamethasone, prednisolone and prednisone, revealed that AI occurred in nearly all children in the first days after discontinuation of glucocorticoids.[@R13] However, the precise duration of glucocorticoid therapy and tapering protocol were not reported in the majority of the studies. While most of the children recovered within several weeks, a few children had prolonged AI lasting up to 34 weeks. Fluconazole was noted in one of these studies to possibly prolong the duration of AI while another study identified stress and infection to be risk factors.[@R15]

A meta-analysis examining the role of inhaled corticosteroids (ICS) in suppression of the HPA axis noted no AI with ICH doses of ≤400 mcg of beclomethasone dipropionate daily.[@R9] However, subsequent reports have noted HPA axis suppression at lower ICS doses.[@R3] Since the bioavailability and bioequivalence of ICS preparations vary along with individual glucocorticoid sensitivity, it is difficult to identify a threshold dose for all ICS that will cause HPA axis suppression.[@R18] Therefore, it is important to recognize chronic ICS therapy as a risk factor for AI. A study of infants with hemangiomas treated with high-dose glucocorticoid therapy for 12--26 weeks demonstrated the return of normal circadian response in salivary cortisol levels within 6 weeks and normal response to administration of low-dose ACTH stimulation by 12 weeks after stopping treatment.[@R14]

During the process of recovery from HPA suppression, physiological circadian secretion of cortisol may recover before return of the ability of the hypothalamus to respond to stress.[@R19] Therefore, a patient may have a normal 8:00 AM cortisol, but still be unable to show an appropriate serum cortisol response to stress.[@R20] The wide variability in timing of recovery of the HPA axis after discontinuation of glucocorticoid exposure emphasizes the need for clinicians to be aware of clinical scenarios with an increased risk of AI.

Diagnosis of acute AI {#s4}
=====================

Triggers {#s4a}
--------

Diagnosis of AI can be challenging as the clinical signs are not specific and may progress insidiously over time. Adrenal crisis can be precipitated by acute illness, physical stress or injury requiring increased cortisol production above basal needs in the setting of normal adrenal function. In addition, induction of anesthesia and surgery can precipitate acute AI.

Clinical signs {#s4b}
--------------

Acute AI can present with fatigue, weakness, tachycardia, hypotension, dizziness, nausea, vomiting, abdominal pain, diaphoresis and seizures. If unrecognized and not treated quickly, AI can progress to coma and death.[@R3] Prolonged cholestatic jaundice, failure to gain weight and hypoglycemia may be the presenting clinical features in neonates and infants. Micropenis, bilateral cryptorchidism and, rarely, central diabetes insipidus may also be present in neonates who have AI due to panhypopituitarism. Individuals with primary AI may have hyperpigmentation of the skin (particularly creases, folds and scars), gums and buccal mucosa.

General biochemistry {#s4c}
--------------------

In acute AI, hyponatremia is the most consistent biochemical finding.[@R12] Hyperkalemia is present in primary, but not secondary AI, and can be associated with hypercalcemia and metabolic acidosis. Hypoglycemia is more frequent in neonates and infants regardless of the type of AI. Other findings include normocytic anemia, lymphocytosis and eosinophilia.

Hormonal measurements and provocative testing {#s4d}
---------------------------------------------

The diagnosis of primary AI is suggested by blood tests preferably performed at 8:00 AM that show an ACTH level greater than 100 pg/mL and a cortisol level less than 10 mcg/dL[@R1] or by an ACTH level that is twofold greater than the upper limit of the normal range and a cortisol level less than 5 mcg/dL.[@R8] Low serum aldosterone with elevated plasma renin activity is the hallmark of mineralocorticoid deficiency. Secondary AI is associated with low levels of both cortisol and ACTH. An 8:00 AM serum cortisol level of ≤3 mcg/dL is highly suggestive of the diagnosis whereas a cortisol value of ≥18 mcg/dL essentially excludes AI.[@R1] If AI is suspected during an acute illness, a random cortisol and ACTH should be obtained prior to initiating glucocorticoid therapy. A serum cortisol concentration less than 18 mcg/dL during acute illness can be indicative of AI.[@R12] Cortisol and ACTH levels may be difficult to interpret in neonates and infants as circadian pattern of secretion does not appear until 4 months[@R27] and cortisol-binding globulin is low causing low total, but not free, serum cortisol.

If levels of plasma ACTH and/or serum cortisol are equivocal, dynamic testing of adrenal function with cosyntropin should be done. Typically a high-dose cosyntropin stimulation test is preferred when primary AI is suspected (usual dose is 15 mcg/kg in neonates, 125 mcg in infants \<2 years, and 250 mcg in older children). In secondary AI, dynamic testing with either high or low-dose cosyntropin (1 mcg) has been used for evaluation of the HPA axis. Regardless of the cosyntropin dose used, a serum cortisol level \>18 mcg/dL rules out AI. The low-dose protocol is not universally accepted primarily due to technical factors influencing the test results. A dose of 1 mcg cosyntropin requires preparation by the person carrying out the test. Also, the prepared dilution should be given intravenously without using a catheter made of 'fluorinated ethylene propylene' plastic to which the cosyntropin binds.[@R12]

Treatment {#s5}
=========

There is limited empirical evidence to guide the optimal glucocorticoid stress-dosing of children and adolescents who have AI. While the debate about what constitutes physiological stress is unresolved, several situations are generally accepted as significant stress including: fever \>38°C (100.4°F), intercurrent illness with emesis, prolonged or voluminous diarrhea, infectious disease requiring antibiotics, acute trauma requiring medical intervention (eg, fracture) and anesthesia and associated surgical procedures. Guidelines on cortisol requirement in times of physiological stress have been based on the general acceptance that conditions of maximal stress increase the serum cortisol levels by 2--3 times.[@R1] Treatment recommendations below are based on recent literature on glucocorticoid replacement therapy.

Outpatient prevention of acute AI {#s6}
=================================

General pediatricians and endocrinologists {#s6a}
------------------------------------------

Following the diagnosis of AI, comprehensive educational outreach should include the family and caregivers, the primary care physician, and the local emergency care providers regarding the signs, symptoms and treatment of cortisol deficiency to prevent adrenal crises. Electronic medical records (EMR) may be used to flag patients with known or at high risk for AI to increase provider attention.[@R32]

The first step in preventing acute AI is maintenance glucocorticoid replacement therapy. Maintenance dosing of glucocorticoid is based on the secretory rate of cortisol which has been reported to be 5--8 mg/m^2^/d in healthy controls.[@R34] For primary AI other than CAH, hydrocortisone at 8--12 mg/m^2^/d in 3 divided doses is recommended.[@R1] In CAH, the consensus dosing is 10--15 mg/m^2^/d.[@R36] Patients with secondary AI may be maintained on a lower dose.[@R1]

A challenge with hydrocortisone therapy is its short median elimination half-life, especially in children with CAH (58 minutes (range: 41--105 minutes)) allowing most of the hydrocortisone dose to be eliminated from the body within 4--7 hours.[@R11] To prevent alternating periods of hypocortisolemia and hypercortisolemia throughout each day in children with AI, hydrocortisone should be administered in at least 3 divided doses. A 6-hour pharmacokinetic/pharmacodynamic study in children with CAH showed that maximum suppression of adrenal steroids (17-hydroxyprogesterone and androstenedione) occurs 3--4 hours after hydrocortisone dose and that adrenal steroids rebounded toward elevated baseline concentrations by the end of 6 hours.[@R11] This suggests that the elimination half-life of cortisol is more relevant to adrenal steroid suppression than the biological or pharmacological half-life of cortisol (8 hours).[@R39] Because of hydrocortisone pharmacokinetic properties and in order to mimic physiological circadian cortisol profiles, the highest hydrocortisone dose should be given in the morning.[@R11]

Long-acting glucocorticoids such as dexamethasone, prednisone and prednisolone are not recommended for maintenance glucocorticoid therapy in growing children.[@R26] The use of long-acting glucocorticoids, such as dexamethasone, in treatment of initial adrenal crisis will prevent the provider from performing an ACTH stimulation test during the initial hospitalization to establish the definitive diagnosis. Prednisolone and dexamethasone are 15-fold and 80--100-fold more potent, respectively, than hydrocortisone in terms of growth suppression.[@R42] A modified-release formulation of hydrocortisone (Chronocort) given twice daily has been studied in adults with CAH[@R44] but failed to meet the phase 3 trial primary objective confirming its superiority over conventional treatment.[@R45]

During infancy to early childhood, smaller doses and incremental adjustments are required to avoid the adverse effects of glucocorticoid excess including obesity, hypertension, impaired growth, osteoporosis and insulin resistance. However, lack of availability of tablets in strengths lower than 5 mg makes dosing of infants difficult and less precise. Currently there is no commercially available liquid formulation that provides dosing in 0.1 mg increments since withdrawal of hydrocortisone cypionate suspension in 2001.[@R46] Quartering 5 mg (6.5 mm) or 10 mg (8 mm) hydrocortisone tablets can lead to inconsistent cortisol levels and result in either undertreatment or overtreatment due to unacceptable dose variability.[@R47] Crushed, weighed hydrocortisone capsules from a compounding pharmacy may also lead to inconsistent cortisol levels and overtreatment.[@R49] Alcohol-free hydrocortisone oral suspension (2 mg/mL) prepared from 10 mg tablets provides good dose repeatability when shaken before use and was stable for 90 days when stored in either a bottle or syringe at either 4°C or 25°C.[@R51] A pharmacokinetic study in children with CAH showed no difference in the extent or rate of hydrocortisone absorption between alcohol-free hydrocortisone suspension prepared from 10 mg tablets by a compounding pharmacy and hydrocortisone tablets.[@R52] Future studies may encourage the development of a Food and Drug Administration (FDA)-approved commercially available alcohol-free hydrocortisone suspension. Uncoated minitablets of 2.5 mg (3 mm) could also be an alternative.[@R48] Multiparticulate hydrocortisone granules (Alkindi) with doses of 0.5, 1, 2 and 5 mg have been recently licensed in Europe.[@R55]

In this guideline, we outline an Adrenal Insufficiency Action Plan ([figure 2](#F2){ref-type="fig"}) and an Adrenal Insufficiency Instructions for Emergency Room Staff ([figure 3](#F3){ref-type="fig"}), a stepwise approach to hydrocortisone dosing during illness similar to the extremely successful Asthma Action Plan.[@R56] Our goal is to provide clear guidance for caregivers, primary care physicians, urgent care and emergency providers for appropriate stress dosing of hydrocortisone or its equivalent in children with known AI during illness and surgical procedures to prevent and treat adrenal crisis. The Adrenal Insufficiency Action Plan provides instructions for oral stress dosing with hydrocortisone (double or triple the daily dose given every 6--8 hours) and injectable hydrocortisone dosing when unable to take oral stress dose. All children with AI should be provided with an individualized care plan (Adrenal Insufficiency Action Plan and/or medical letter, see [figures 1, 2 and 3](#F1 F2 F3){ref-type="fig"}), which could be made available in EMRs. The use of such tools has been shown to improve patient education regarding management of physiological stress in outpatient settings.[@R32] In addition, children with AI need a medical alert identification for EMS personnel.

![Adrenal Insufficiency Emergency Care Letter.](jim-2019-000999f01){#F1}

![Adrenal Insufficiency Action Plan.](jim-2019-000999f02){#F2}

![Adrenal Insufficiency Instructions for Emergency Room Staff. CBC, complete blood count; IV, intravenous.](jim-2019-000999f03){#F3}

All caregivers should be educated on the use of injectable intramuscular hydrocortisone sodium succinate in the event of emesis or an altered state of consciousness. As administration of intramuscular hydrocortisone sodium succinate requires multiple preinjection steps, a prefilled, single-use autoinjector (ZENEO Hydrocortisone) is in development in France. The use of rectal hydrocortisone suppositories in the management of adrenal crisis may not achieve desired cortisol concentrations.[@R57]

EMS and hospital transport treatment of acute AI {#s6b}
------------------------------------------------

Children with known AI requiring EMS transport should receive an intramuscular injection of potentially life-saving hydrocortisone sodium succinate as soon as possible by the family/caretaker or by EMS providers either using the family's supply or having hydrocortisone sodium succinate available in the EMS vehicles, including mobile care units. Prolonged transportation times for patients living in rural areas may delay administration for several hours further underscoring the importance of EMS access to hydrocortisone sodium succinate. Clearly, local and state regulations and provider practice scope need to be considered by the agency's medical director prior to implementation. In addition, we need to advocate that local and state regulations be updated to support the emergent administration of hydrocortisone sodium succinate by EMS personnel outside the hospital to individuals with known AI. A small number of states and provinces have legislation allowing administration of patient-carried medication and have EMS glucocorticoid protocols in place.[@R58] In this emergency setting, hydrocortisone sodium succinate should be administered at 50--100 mg/m^2^ intramuscularly (5--10 times the physiologic cortisol secretory rate).[@R1] The Endocrine Society Clinical Practice Guideline suggests stress doses of hydrocortisone sodium succinate based on patient's age: children ≤3 years: 25 mg; school-age children (\>3 and \<12 years): 50 mg; and older children and adolescents (≥12 years): 100 mg as an initial stress dose.[@R26] We recommend using the 100 mg/2 mL vial as its dilution is simple if smaller doses are needed. Finally, we also recommend adding age-related hydrocortisone sodium succinate dosing to weight-based dosing tapes used in emergency care of children, as their use is ubiquitous.[@R63]

Regarding other glucocorticoids, dexamethasone sodium phosphate (1.5--2 mg/m^2^/dose)[@R1] has been available in some EMS settings and used in secondary AI. However, it is not suitable for treatment of salt-wasting adrenal crisis in primary AI because it has no mineralocorticoid effect. Methylprednisolone sodium succinate (10--25 mg/m^2^/dose intramuscular) may be used to treat adrenal crisis although it has less mineralocorticoid activity than hydrocortisone.[@R64]

ED treatment of adrenal crisis {#s7}
==============================

Vague and non-specific symptoms of AI make the diagnosis of adrenal crisis easily overlooked in the ED triage process. Hypotension and hypoglycemia can develop suddenly in the ED,[@R65] even after normal triage assessments. Providers must exercise a high index of suspicion for adrenal crisis in any child who is at risk of AI ([table 1](#T1){ref-type="table"} and [box 1](#B1){ref-type="boxed-text"}). In cases of known AI the ED letter ([figure 1](#F1){ref-type="fig"}, modified from ref [@R66]) or Adrenal Insufficiency Action Plan should be given to triage personnel on arrival to the ED to speed the process.

The initial stress dose of hydrocortisone sodium succinate given by family, EMS, or in ED should be followed by 50--100 mg/m^2^/d divided into 4 doses given every 6 hours or given by continuous infusion.[@R1] In the ED, intravenous dosing is preferred for the initial stress dose, however, if an intravenous catheter cannot be placed quickly, the initial dose should be given intramuscularly. Ongoing stress doses are typically given parenterally for the first 24--48 hours and then transitioned to oral dosing if feasible. Because hydrocortisone sodium succinate in high doses has mineralocorticoid effect, no fludrocortisone is needed while the patient receives intravenous fluids and stress doses of hydrocortisone.

Appropriate evaluation (as described above) should include biochemical documentation of the AI (serum cortisol and plasma ACTH levels), assessment of hydration and acid-base status, and investigation of an underlying precipitant. Ideally, a blood sample should be collected prior to administration of hydrocortisone sodium succinate, especially for patients with a suspected new diagnosis of AI; however, treatment should *NOT* be delayed if obtaining a blood sample proves difficult.

In an acute adrenal crisis, hypovolemia should be rapidly reversed with a 20 mL/kg bolus of isotonic solution, preferably normal saline. Hypoglycemia should be treated with a 2.5 mL/kg bolus of 10% dextrose solution and repeated if the response is not adequate.

###### Summary of recommendations

-   Patients with known AI and their families should be provided an Adrenal Insufficiency Action Plan, including maintenance hydrocortisone dose, stress dose for hydrocortisone (both oral and intramuscular/intravenous) and contact information for their endocrinologist. They should be instructed to keep this with them at all times and to provide it immediately to EMS providers and triage personnel in urgent care and emergency departments.

-   All patients with known AI should carry medical alert identification indicating the diagnosis and glucocorticoid dependency.

-   Families should be educated to use intramuscular hydrocortisone sodium succinate for emergency situations.

-   Development of FDA-approved hydrocortisone formulations that allow for smaller, more precise dosing in infants and young children with AI.

-   Awareness of the multiple potential causes of AI, including glucocorticoid therapy for other conditions, and a high index of suspicion for AI in children presenting with hypoglycemia, hyponatremia and hypotension is necessary to identify new cases of AI and urgently treat adrenal crises.

-   Acute adrenal crisis requires rapid treatment of hypovolemia, hyponatremia, and hypoglycemia with normal saline and 10% dextrose intravenously in addition to stress dose hydrocortisone administration.

-   Hydrocortisone should be added to weight-based dosing tapes.

-   Emergency medical transport services should be aware of and emphasize emergency administration of stress dose hydrocortisone sodium succinate within constraints of their systems. Advocacy efforts to increase the availability of stress dose hydrocortisone sodium succinate (Solu-Cortef Act-o-Vial, preferably 100mg/2mL) during emergency medical transport care, including mobile care units, are highly encouraged.

Conclusions {#s8}
===========

Patients with AI (primary or secondary) may present to EMS personnel or the ED in an acute life-threatening crisis needing prompt and effective management to avoid severe consequences. This document offers evidence and consensus-based expert guidelines for most effective management of AI in the emergent scenario. A high index of suspicion needs to be maintained in all patients at risk for acute adrenal crisis.
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